/TVTX
TVTX Stock - Travere Therapeutics, Inc.
Healthcare|BiotechnologyNASDAQ
$34.51+0.06%
+$0.02 (+0.06%) • Dec 19
68
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.91
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).53
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.84
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+1.4%upside
Target: $34.99
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for TVTX
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$34.16 – $34.86
TARGET (TP)$35.00
STOP LOSS$31.75
RISK/REWARD1:0.2
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.89
52W High$37.50
52W Low$12.91
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $233.18M | $145.24M | $109.46M | $131.84M | $198.32M |
| Gross Profit | $225.43M | $133.79M | $105.04M | $128.02M | $192.19M |
| Gross Margin | 96.7% | 92.1% | 96.0% | 97.1% | 96.9% |
| Operating Income | $-323,827,000 | $-388,138,000 | $-319,813,000 | $-199,425,000 | $-176,163,000 |
| Net Income | $-321,545,000 | $-111,399,000 | $-278,482,000 | $-180,091,000 | $-169,431,000 |
| Net Margin | -137.9% | -76.7% | -254.4% | -136.6% | -85.4% |
| EPS | $-4.08 | $-1.50 | $-4.37 | $-3.01 | $-3.56 |
Company Overview
Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in gallbladders; Cholbam, a cholic acid capsule to treat pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects, as well as for adjunctive treatment of patients with peroxisomal disorders; and Thiola and Thiola EC, a tiopronin tablet for the treatment of homozygous cystinuria. The company's product candidates also consist of Sparsentan, which is in Phase III clinical trial for the treatment of focal segmental glomerulosclerosis and immunoglobulin A nephropathy; and TVT-058, a novel investigational human enzyme replacement candidate, which is in Phase I/II clinical trials for the treatment of classical homocystinuria. It has a cooperative research and development agreement with National Institutes of Health's National Center for Advancing Translational Sciences and patient advocacy organizations, CDG Care, and Alagille Syndrome Alliance for the identification of potential small molecule therapeutics for NGLY1 deficiency and Alagille syndrome. The company was formerly known as Retrophin, Inc. and changed its name to Travere Therapeutics, Inc. in November 2020. Travere Therapeutics, Inc. was incorporated in 2008 and is headquartered in San Diego, California.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
11
61%
Hold / Neutral
6
33%
Sell / Underperform
1
6%
Analyst Consensus🟡 Mixed
11 Bullish7 Neutral/Bearish
Price Targets
$26
Average Target
↓ 24.2% Downside
Now
$7
Low
$26
Average
$48
High
Based on 18 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| October 31st 2025 | Citigroup | Reiterated | Buy | $48← $34 |
| June 11th 2025 | H.C. Wainwright | Resumed | Buy | $30 |
| June 11th 2025 | Citigroup | Reiterated | Buy | $32← $35 |
| January 10th 2025 | Cantor Fitzgerald | Initiation | Overweight | - |
| October 21st 2024 | Wells Fargo | Upgrade | Overweight | $27← $9 |
| October 16th 2024 | Scotiabank | Initiation | Sector Outperform | - |
| September 9th 2024 | Guggenheim | Upgrade | Buy | $25 |
| March 27th 2024 | Guggenheim | Downgrade | Neutral | - |
| December 5th 2023 | Citigroup | Upgrade | Buy | $10← $7 |
| November 20th 2023 | Citigroup | Initiation | Neutral | $7 |
| September 22nd 2023 | Wells Fargo | Downgrade | Equal Weight | $8← $24 |
| September 21st 2023 | William Blair | Downgrade | Market Perform | - |
| September 6th 2023 | Evercore ISI | Resumed | Outperform | $30 |
| July 21st 2023 | JP Morgan | Initiation | Overweight | $26 |
| June 7th 2023 | Piper Sandler | Resumed | Neutral | $22 |
Earnings History & Surprises
TVTXBeat Rate
44%
Last 18 quarters
Avg Surprise
+5.1%
EPS vs Estimate
Beats / Misses
8/9
1 met exactly
Latest EPS
$0.28
Q4 2025
EPS Surprise History
Q1 24
+8.7%
$-1.16vs$-1.27
Q2 24
-79.6%
$-1.76vs$-0.98
Q3 24
-3.4%
$-0.90vs$-0.87
Q4 24
0.0%
$-0.70vs$-0.70
Q1 25
-25.9%
$-0.73vs$-0.58
Q2 25
+14.5%
$-0.47vs$-0.55
Q3 25
+50.0%
$-0.14vs$-0.28
Q4 25
+190.3%
$0.28vs$-0.31
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | Apr 29, 2026 | — | — | — | — |
Q1 2026 | Feb 19, 2026 | $-0.05 | — | — | — |
Q4 2025 | Oct 30, 2025 | $-0.31 | $0.28 | +190.3% | ✓ BEAT |
Q3 2025 | Aug 6, 2025 | $-0.28 | $-0.14 | +50.0% | ✓ BEAT |
Q2 2025 | May 1, 2025 | $-0.55 | $-0.47 | +14.5% | ✓ BEAT |
Q1 2025 | Feb 20, 2025 | $-0.58 | $-0.73 | -25.9% | ✗ MISS |
Q4 2024 | Oct 31, 2024 | $-0.70 | $-0.70 | 0.0% | = MET |
Q3 2024 | Aug 1, 2024 | $-0.87 | $-0.90 | -3.4% | ✗ MISS |
Q2 2024 | May 6, 2024 | $-0.98 | $-1.76 | -79.6% | ✗ MISS |
Q1 2024 | Feb 15, 2024 | $-1.27 | $-1.16 | +8.7% | ✓ BEAT |
Q4 2023 | Nov 7, 2023 | $-1.09 | $-1.17 | -7.3% | ✗ MISS |
Q3 2023 | Aug 3, 2023 | $-1.16 | $-1.13 | +2.6% | ✓ BEAT |
Q2 2023 | May 4, 2023 | $-1.18 | $-1.27 | -7.6% | ✗ MISS |
Q1 2023 | Feb 23, 2023 | $-1.04 | $-1.03 | +1.0% | ✓ BEAT |
Q4 2022 | Oct 27, 2022 | $-0.97 | $-1.09 | -12.4% | ✗ MISS |
Q3 2022 | Aug 4, 2022 | $-0.94 | $-1.05 | -11.7% | ✗ MISS |
Q2 2022 | May 5, 2022 | $-0.85 | $-1.20 | -41.2% | ✗ MISS |
Q1 2022 | Feb 24, 2022 | $-0.72 | $-0.84 | -16.7% | ✗ MISS |
Q4 2021 | Oct 28, 2021 | $-0.72 | $-0.59 | +18.1% | ✓ BEAT |
Q3 2021 | Jul 29, 2021 | $-0.73 | $-0.64 | +12.3% | ✓ BEAT |
Latest News
HC Wainwright & Co. Reiterates Buy on Travere Therapeutics, Maintains $47 Price Target
📈 PositiveBenzinga•Nov 28, 2025, 11:57 AM
Piper Sandler Maintains Neutral on Travere Therapeutics, Raises Price Target to $35
➖ NeutralBenzinga•Nov 4, 2025, 04:35 PM
TD Cowen Maintains Buy on Travere Therapeutics, Raises Price Target to $40
📈 PositiveBenzinga•Oct 31, 2025, 06:07 PM
Travere Therapeutics shares are trading higher after the company reported better-than-expected Q3 sales results.
📈 PositiveBenzinga•Oct 31, 2025, 01:00 PM
Travere Therapeutics shares are trading higher after the company reported better-than-expected Q3 sales results.
📈 PositiveBenzinga•Oct 30, 2025, 08:35 PM
Travere Therapeutics Q3 Adj. EPS $0.59, Sales $164.859M Beat $106.534M Estimate
📈 PositiveBenzinga•Oct 30, 2025, 08:02 PM
Travere Therapeutics To Present 11 Abstracts, Including A Late-Breaking Poster At American Society Of Nephrology Kidney Week 2025 In Houston, TX November 6-9 Highlights Including Data Duplex Study Showing More Filspari-Treated Patients Achieved Proteinuria Below 0.7 G/g Compared With Irbesartan, Indicating Reduced Kidney Failure Risk In FSGS
📈 PositiveBenzinga•Oct 17, 2025, 01:09 PM
Travere Therapeutics shares are trading higher. Guggenheim issued a Buy rating on the stock and a price target of $47.
📈 PositiveBenzinga•Oct 6, 2025, 05:02 PM
KDIGO 2025 Guidelines Endorse FILSPARI By CSL Vifor And Travere Therapeutics Backed By PROTECT Trial Evidence For IgA Nephropathy
📈 PositiveBenzinga•Sep 26, 2025, 07:24 AM
HC Wainwright & Co. Reiterates Buy on Travere Therapeutics, Maintains $47 Price Target
📈 PositiveBenzinga•Sep 19, 2025, 12:19 PM
Stifel Maintains Hold on Travere Therapeutics, Raises Price Target to $25
➖ NeutralBenzinga•Sep 12, 2025, 02:29 PM•Also:
Wells Fargo Maintains Overweight on Travere Therapeutics, Raises Price Target to $35
📈 PositiveBenzinga•Sep 11, 2025, 12:38 PM
HC Wainwright & Co. Reiterates Buy on Travere Therapeutics, Maintains $47 Price Target
📈 PositiveBenzinga•Sep 10, 2025, 04:40 PM
Travere Therapeutics shares are trading higher after the company announced that it was informed by the FDA that an advisory committee is no longer needed following further review of its supplemental New Drug Application for FILSPARI in focal segmental glomerulosclerosis.
📈 PositiveBenzinga•Sep 10, 2025, 01:03 PM
Travere rises as FDA says no AdCom required for Filspari label expansion
📈 PositiveSeeking Alpha•Sep 10, 2025, 11:21 AM
Travere Therapeutics Announces FDA Drops Advisory Committee For FILSPARI sNDA In FSGS; PDUFA Target Date Set For January 13, 2026
📈 PositiveBenzinga•Sep 10, 2025, 11:03 AM
HC Wainwright & Co. Reiterates Buy on Travere Therapeutics, Maintains $47 Price Target
📈 PositiveBenzinga•Sep 3, 2025, 02:41 PM
UPDATE: Travere Therapeutics Presents Long-Term Safety And Efficacy Data For Pegtibatinase In Classical Homocystinuria
📈 PositiveBenzinga•Sep 3, 2025, 12:46 PM
Travere Therapeutics To Restart Phase 3 Clinical Trial For Its HCU Treatment
📈 PositiveBenzinga•Sep 3, 2025, 11:04 AM
Travere Therapeutics shares are trading higher after HC Wainwright & Co. raised its price target on the stock from $30 to $47.
📈 PositiveBenzinga•Aug 28, 2025, 12:57 PM
Frequently Asked Questions about TVTX
What is TVTX's current stock price?
Travere Therapeutics, Inc. (TVTX) is currently trading at $34.51 per share. The stock has moved +0.06% today.
What is the analyst price target for TVTX?
The average analyst price target for TVTX is $35.00, based on 1 analyst.
What sector is Travere Therapeutics, Inc. in?
Travere Therapeutics, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is TVTX's market cap?
Travere Therapeutics, Inc. has a market capitalization of $3.09 billion, making it a mid-cap company.
Does TVTX pay dividends?
No, Travere Therapeutics, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorAAPG
ASCENTAGE PHARMA GROUP INTERNATIONAL
$29.31
Mkt Cap: $2.7B
APGE
Apogee Therapeutics, Inc.
$78.54
Mkt Cap: $4.3B
CELC
Celcuity Inc.
$101.16
Mkt Cap: $4.7B
CGON
CG Oncology, Inc. Common stock
$39.03
Mkt Cap: $2.9B
CNTA
Centessa Pharmaceuticals plc
$24.85
Mkt Cap: $3.3B
IRON
Disc Medicine, Inc.
$80.04
Mkt Cap: $3.0B
LEGN
Legend Biotech Corporation
$21.92
Mkt Cap: $2.0B
RARE
Ultragenyx Pharmaceutical Inc.
$33.50
Mkt Cap: $3.2B
TARS
Tarsus Pharmaceuticals, Inc.
$81.40
Mkt Cap: $3.5B
XENE
Xenon Pharmaceuticals Inc.
$44.10
Mkt Cap: $3.4B
Explore stocks similar to TVTX for comparison